Based on the results of the global, phase III COLUMBUS trial [8, 9], the BRAF/MEK inhibitor combination, encorafenib plus binimetinib, was approved in Japan in early 2019 for the treatment of BRAF-mutant, at the V600 locus (BRAF V600), unresectable malignant melanoma [10]. Here, BRAF is linked to melanoma.